BOTHELL, WA- Mar 16, 2016 – Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that they have entered into a license agreement covering the company’s SMARTICLES and DiLA2 platforms for the delivery of an undisclosed genome editing technology. The agreement is notable in that it provides an exclusive access to Marina’s SMARTICLES and DiLA2 platforms for a different gene editing field than was announced on February 17, 2016. This represents the first time that the company’s combined delivery platforms, SMARTICLES and DiLA2 technologies, have been licensed in connection with gene editing. Under terms of the agreement, Marina could receive up to $40 MM in success based milestones. Further details of the agreement were not disclosed.